BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

Akcea Therapeutics Inc. (NASDAQ:AKCA) said William Andrews will succeed Louis O’Dea as CMO. Andrews joins the rare disease company from Acer Therapeutics Inc. (NASDAQ:ACER), where he was CMO. Rare disease company Strongbridge Biopharma plc (NASDAQ:SBBP)...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
Items per page:
1 - 2 of 2
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

Akcea Therapeutics Inc. (NASDAQ:AKCA) said William Andrews will succeed Louis O’Dea as CMO. Andrews joins the rare disease company from Acer Therapeutics Inc. (NASDAQ:ACER), where he was CMO. Rare disease company Strongbridge Biopharma plc (NASDAQ:SBBP)...
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...
Items per page:
1 - 2 of 2